Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Melanoma

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 7 articles:
HTML format

Single Articles

    April 2022
  1. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.

    March 2022
  2. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    PubMed     Abstract available

    September 2021
  3. CARLINO MS, Larkin J, Long GV
    Immune checkpoint inhibitors in melanoma.
    Lancet. 2021;398:1002-1014.
    PubMed     Abstract available

    June 2020
  4. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    PubMed     Abstract available

  5. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.

    May 2020
  6. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed     Abstract available

    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.